MDM2 SNP309 contributes to tumor susceptibility A meta-analysis》.pdfVIP

Available online at Journal of Genetics and Genomics 38 (2011) 341e350 MDM2 SNP309 contributes to tumor susceptibility: A meta-analysis Xiaoman Wo a,1, Dong Han a,1, Haiming Sun a, Yang Liu a, Xiangning Meng a, Jing Bai a, Feng Chen a, Yang Yu a, Yan Jin a,b, Songbin Fu a,* a Laboratory of Medical Genetics, Harbin Medical University, Harbin 150081, China b Key Laboratory of Medical Genetics (Harbin Medical University), Heilongjiang Higher Education Institutions, Harbin 150081, China Received 3 March 2011; revised 18 July 2011; accepted 18 July 2011 Abstract The potentially functional polymorphism, SNP309, in the promoter region of MDM2 gene has been implicated in cancer risk, but individual published studies showed inconclusive results. To obtain a more precise estimate of the association between MDM2 SNP309 and risk of cancer, we performed a meta-analysis of 70 individual studies in 59 publications that included 26,160 cases with different types of tumors and 33,046 controls. Summary odds ratios (OR) and corresponding 95% confidence intervals (CIs) were estimated using fixed- and random-effects models when appropriate. Overall, the variant genotypes were associated with a significantly increased cancer risk for all cancer types in different genetic models (GG vs. TT: OR, 1.123; 95% CI, 1.056e1.193; GG/GT vs. TT: OR, 1.028; 95% CI, 1.006e1.050). In the stratified analyses, the increased risk remained for the studies of most types of cancers, Asian populations, and hospital- /population-based studies in different genetic models, whereas s